Healthcare is bullish on AI
It’s only been about two years since healthcare really started adopting generative AI. Now, it’s no longer just demos testing out transcription tools. Timed to the HIMSS conference, Microsoft, Google ...
View ArticleModerna stands by its Covid vaccine patents after PTAB decision
Moderna says its long-running patent dispute with Pfizer and BioNTech isn't over, even after a decision by an administrative tribunal that invalidated two of its Covid-19 vaccine-related patents. The...
View ArticleWalgreens to go private in $10B deal
Walgreens is entering a new chapter as it agrees to sell itself to a private equity firm, ending its rocky run as a publicly traded company. New York-based Sycamore Partners is acquiring the retail...
View ArticleJ&J axes Phase 3 depression program due to ‘insufficient efficacy’ shortly...
Johnson & Johnson scrapped its Phase 3 program for aticaprant, an experimental and new type of major depressive disorder drug, following "insufficient efficacy," the pharma giant disclosed late...
View ArticleTune’s CEO search ends as John McHutchison takes top spot; More from Pfizer’s...
John McHutchison started Monday as CEO and chairman of Tune Therapeutics, after sitting on the company’s board for two years. One message he wants to make clear: “We’re not a gene ...
View ArticleRoche launches new research center with Harvard in Boston area
Roche announced a new research hub on Friday in partnership with Harvard that it hopes will accelerate efforts in disease biology, engineering and AI. The hub will be called the Roche Genentech...
View ArticleCytomX, Amgen pass on T cell engager; Molecular Partners ends work with Novartis
Plus, news about Atea Pharmaceuticals: CytomX, Amgen stop work on T cell engager: The partners decided to end development of an EGFR-targeting T cell engager based on “clinical observations to date ...
View ArticleJeb Keiper steps down from Nimbus CEO post, business chief to take over
Nimbus Therapeutics is getting a new CEO after more than six years, as Jeb Keiper passes the baton to Abbas Kazimi. Keiper spent over a decade at Nimbus, starting as its chief business officer in ...
View ArticleAt $300M Kardigan startup, former MyoKardia team unveils its first drug, and...
When some former MyoKardia execs reunited with $300 million for a new "heart health" biotech earlier this year, they were tight-lipped about their in-licensed clinical-stage assets. The company ...
View ArticleWhat FDA, NIH hearings say about Trump drug, health policy
President Donald Trump's nominees for NIH director and FDA commissioner sailed through their respective confirmation hearings this week, facing few difficult questions and offering few controversial...
View ArticleHow bluebird's buyout offer went from $100M upfront to $29M
Bluebird bio went from a high-flying $10 billion company in 2018 during the heyday of gene therapy to being sold for a measly $29 million upfront in a fire sale last month. But it almost ...
View ArticleBayer eyes capital raise as it grapples with Monsanto cases
Bayer is asking shareholders to authorize a potential equity offer that would allow it to quickly raise billions of euros to deal with ongoing Monsanto litigation. The company requested an equity...
View ArticleFDA approves Neurotech therapy for rare eye disease
The FDA on Thursday approved Neurotech Pharmaceuticals’ cell therapy for an eye disease known as macular telangiectasia type 2, which causes central vision to become distorted and get worse over time ...
View ArticleStart of 2025 comes with generic drug price decreases, several major...
More generic drug prices decreased than increased in January, a new report from 46Brooklyn found. The report said for every generic drug price increase in January, 1.3 generic drugs saw their ...
View ArticleFDA and NIH nominees sail through Senate hearings; Tariffs’ early impact on...
Welcome back to Endpoints Weekly! This week was another busy one in DC, with two Senate hearings for Trump’s picks to lead the NIH and FDA, more actions from the Department of Government Efficiency,...
View ArticleSun Pharma to acquire Checkpoint Therapeutics and its anti-PD-L1 antibody
After months of searching for a partner for its recently approved cancer drug, Checkpoint Therapeutics has instead secured a buyer. India's Sun Pharma is acquiring the immuno-oncology biotech for $4.10...
View ArticleNovo Nordisk’s CagriSema shows 15.7% weight loss in second pivotal trial
Novo Nordisk’s CagriSema demonstrated weight loss of 15.7% in patients with both obesity and type 2 diabetes who took the drug for more than a year, the company said Monday. ...
View ArticleArrowhead reveals small batch of open-label data for 'non-core' kidney drug
Arrowhead Pharmaceuticals on Monday shared new open-label data in about a dozen patients for a program designed to improve certain kidney disease outcomes by targeting complement pathways. The program,...
View ArticleTrevi Therapeutics stock soars on Phase 2a chronic cough data
Trevi Therapeutics’ chronic cough drug reduced patients’ 24-hour cough frequency by 57% compared to placebo in a Phase 2a trial, exceeding investors’ expectations. The company’s stock {$TRVI} soared...
View ArticleJ&J, Protagonist outline first IBD win for potential immunological blockbuster
Johnson & Johnson and Protagonist Therapeutics have bet their oral IL-23 drug will be an immunology blockbuster, and they are now one step closer to that goal. The companies said Monday that the...
View Article